IN8bio Inc. (INAB)
| Bid | 0.26 |
| Market Cap | 19.57M |
| Revenue (ttm) | 5.74M |
| Net Income (ttm) | -48.82M |
| EPS (ttm) | -0.74 |
| PE Ratio (ttm) | -0.36 |
| Forward PE | -0.93 |
| Analyst | Buy |
| Ask | 0.27 |
| Volume | 3,390,026 |
| Avg. Volume (20D) | 5,459,418 |
| Open | 0.27 |
| Previous Close | 0.27 |
| Day's Range | 0.26 - 0.29 |
| 52-Week Range | 0.22 - 1.74 |
| Beta | 0.05 |
About INAB
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clini...
Analyst Forecast
According to 4 analyst ratings, the average rating for INAB stock is "Buy." The 12-month stock price forecast is $6.25, which is an increase of 2214.81% from the latest price.
1 year ago · proactiveinvestors.com
IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatmentIN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan drug designation from the US Food and Drug Adminis...
